190:
noted that docetaxel plus zoledronic acid "was associated with similar improvements, although the benefit observed was smaller". The overall conclusion was that "standard of care should be updated to include docetaxel chemotherapy in suitable patients with metastatic disease, and docetaxel may be considered for men with high-risk non-metastatic prostate cancer with or without radiotherapy".
41:
189:
reported that "the addition of docetaxel to standard of care was associated with improved survival, with an HR of 0·78 and a difference in median survival of 10 months, as well as improvements in prostate-cancer-specific survival, failure-free survival, and skeletal-related events". They also
357:
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; et al. (19 March 2016), "Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial",
196:
reported on radiotherapy. For patients with a high metastatic burden the radiotherapy did not improve survival. No improvement was noted for unselected patients, but for men with a low burden overall survival did improve. There is some discussion as to how the burden is identified (CT and bone
415:
Parker, Christopher C; James, Nicholas D; Brawley, Christopher D; et al. (1 December 2018), "Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial",
341:
226:
67:
The men are randomly assigned to one of a number of "arms". The primary outcome by which the arms were judged is overall survival.
79:
48:
STAMPEDE is an acronym for "Systemic
Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy".
64:. 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial.
32:. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
480:
475:
210:
adding abiraterone to hormone therapy improves overall survival and delays the time until the cancer gets worse
207:
adding docetaxel to hormone therapy improves the length of time men live – this is called overall survival
213:
adding radiotherapy to hormone therapy in men with less prostate cancer spread improves overall survival
197:
scans versus PET). The findings may also be applicable to other cancers where there is a small volume.
398:"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)"
343:
A trial looking at hormone therapy with other treatments for prostate cancer (STAMPEDE trial results)
443:
385:
433:
425:
375:
367:
99:
61:
29:
397:
22:
Systemic
Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
438:
380:
429:
371:
469:
87:
16:
Clinical trial investigating treatments for high risk or terminal prostate cancer
57:
40:
119:
83:
447:
389:
28:) is a clinical trial investigating treatments for high risk or terminal
70:
The following arms are documented in the publicly available literature.
260:
258:
256:
254:
252:
250:
248:
246:
244:
242:
39:
44:
Differences between healthy prostate and a prostate with a tumour
460:
279:
277:
275:
273:
296:
294:
292:
264:
178:
SOC with transdermal oestradiol replacing standard ADT.
162:
SOC plus abiraterone and enzalutamide and prednisolone.
56:The trial investigates new approaches for men with
283:
200:
193:
324:
312:
300:
227:Prostate Adenocarcinoma: TransCutaneous Hormones
186:
146:SOC plus abiraterone acetate and prednisolone.
110:Standard care plus docetaxel and prednisolone.
82:(ADT). After 2015 SOC was expanded to include
8:
396:Medical Research Council (7 November 2018),
437:
379:
138:SOC plus zoledronic acid and celecoxib.
130:SOC plus zoledronic acid and docetaxel.
238:
216:celecoxib doesn’t help men live longer.
340:Cancer Research UK (31 January 2019),
7:
78:Standard of care (SOC) is lifelong
14:
402:U.S. National Library of Medicine
284:Parker, James & Brawley 2018
194:Parker, James & Brawley 2018
90:(RT) at the start of treatment.
203:presents the main findings as:
325:James, Sydes & Clarke 2016
313:James, Sydes & Clarke 2016
301:James, Sydes & Clarke 2016
187:James, Sydes & Clarke 2016
1:
430:10.1016/S0140-6736(18)32486-3
372:10.1016/S0140-6736(15)01037-5
265:Medical Research Council 2018
80:androgen deprivation therapy
497:
201:Cancer Research UK 2019
45:
60:and locally advanced
43:
424:(10162): 2353–2366,
170:SOC plus metformin.
366:(10024): 1163–77,
52:Aims and procedure
46:
488:
461:STAMPEDE website
450:
441:
411:
410:
408:
392:
383:
353:
352:
350:
328:
322:
316:
310:
304:
298:
287:
281:
268:
262:
496:
495:
491:
490:
489:
487:
486:
485:
481:Clinical trials
476:Prostate cancer
466:
465:
457:
414:
406:
404:
395:
356:
348:
346:
339:
336:
331:
327:, p. 1175.
323:
319:
315:, p. 1173.
311:
307:
299:
290:
282:
271:
263:
240:
236:
223:
184:
176:
168:
160:
152:
144:
136:
128:
116:
108:
100:zoledronic acid
96:
76:
62:prostate cancer
54:
38:
30:prostate cancer
17:
12:
11:
5:
494:
492:
484:
483:
478:
468:
467:
464:
463:
456:
455:External links
453:
452:
451:
412:
393:
354:
335:
332:
330:
329:
317:
305:
288:
269:
237:
235:
232:
231:
230:
222:
219:
218:
217:
214:
211:
208:
183:
180:
175:
172:
167:
164:
159:
156:
151:
148:
143:
140:
135:
132:
127:
124:
115:
112:
107:
104:
95:
92:
75:
72:
53:
50:
37:
34:
15:
13:
10:
9:
6:
4:
3:
2:
493:
482:
479:
477:
474:
473:
471:
462:
459:
458:
454:
449:
445:
440:
435:
431:
427:
423:
419:
413:
403:
399:
394:
391:
387:
382:
377:
373:
369:
365:
361:
355:
345:
344:
338:
337:
333:
326:
321:
318:
314:
309:
306:
302:
297:
295:
293:
289:
285:
280:
278:
276:
274:
270:
266:
261:
259:
257:
255:
253:
251:
249:
247:
245:
243:
239:
233:
228:
225:
224:
220:
215:
212:
209:
206:
205:
204:
202:
198:
195:
191:
188:
181:
179:
173:
171:
165:
163:
157:
155:
154:SOC plus RT.
149:
147:
141:
139:
133:
131:
125:
123:
121:
113:
111:
105:
103:
101:
93:
91:
89:
85:
81:
73:
71:
68:
65:
63:
59:
51:
49:
42:
35:
33:
31:
27:
23:
19:
421:
417:
405:, retrieved
401:
363:
359:
347:, retrieved
342:
334:Bibliography
320:
308:
199:
192:
185:
177:
169:
161:
153:
145:
137:
129:
117:
109:
97:
88:radiotherapy
77:
69:
66:
55:
47:
25:
21:
20:
18:
470:Categories
418:The Lancet
407:12 October
360:The Lancet
349:12 October
234:References
58:metastatic
120:celecoxib
118:SOC plus
98:SOC plus
84:docetaxel
448:30355464
390:26719232
221:See also
26:STAMPEDE
439:6269599
381:4800035
229:(PATCH)
182:Results
446:
436:
388:
378:
174:Arm L
166:Arm K
158:Arm J
150:Arm H
142:Arm G
134:Arm F
126:Arm E
114:Arm D
106:Arm C
94:Arm B
74:Arm A
444:PMID
409:2019
386:PMID
351:2019
86:and
36:Name
434:PMC
426:doi
422:392
376:PMC
368:doi
364:387
472::
442:,
432:,
420:,
400:,
384:,
374:,
362:,
291:^
272:^
241:^
122:.
102:.
428::
370::
303:.
286:.
267:.
24:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
